EEG coherence and power spectra during REM sleep related to melatonin intake in mild-to-moderate Alzheimer’s disease: a pilot study

Cruz‐Aguilar, Manuel Alejandro; Ramírez‐Salado, Ignacio; Hernández‐González, Marisela; Guevara, Miguel Ángel; Rivera-García, Ana Paula

doi:10.1080/00207454.2021.1928115

Cited by 5 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a previous retrospective study of 50 older adults with MCI shows that 3–9 mg of melatonin supplementation over 9–18 months may improve processing speed, memory, and executive function [68]. A recent pilot study found that 5 mg of melatonin in older adults with mild-moderate AD reduced REM sleep onset but did not examine cognitive decline or AD pathology [69]. While melatonin appears to benefit sleep and has an excellent safety profile [70], human evidence in support of the neuroprotective and neuroinflammative properties which have been found in animal studies remains limited [71,72].…”

Section: What Interventions Have Evidence For Treating Sleep Problems...mentioning

confidence: 99%

Recent advances in understanding of sleep disorders and disturbances for dementia risk and prevention

Lam,

Kong,

Naismith

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of review To synthesise the recent work examining the relationship between sleep disturbances and dementia, emphasising studies involving individuals with mild cognitive impairment (MCI) or Alzheimer's disease (AD) and/or those investigating AD biomarkers. Additionally, we provide an update on recent interventions targeting sleep-related issues in older adults with MCI or AD. Recent findings Various studies have examined obstructive sleep apnoea, sleep duration, and circadian alterations in relation to Alzheimer's pathology and dementia risk, with an emerging body of evidence suggesting that cardiovascular disease, hypertension, glymphatic function, and inflammation might serve as plausible pathophysiological mechanisms contributing to dementia during critical brain periods. Conversely, recent studies investigating insomnia have produced disparate results. Regarding intervention studies, the scarcity of prospective randomised control trials poses a challenge in establishing the benefits of addressing sleep disorders and disturbances. Summary Recent work examining the pathophysiological links between sleep and dementia is strongest for obstructive sleep apnoea and sleep duration, while findings in insomnia studies exhibit inconsistency, possibly due to varied associations with dementia among different insomnia subtypes. It is apparent that more longitudinal studies examining the underlying pathophysiological mechanisms are necessary, alongside more rigorous clinical trials. Although some trials are underway in this field, there is still scarcity in trials examining interventions for circadian disturbances.

show abstract

Section: What Interventions Have Evidence For Treating Sleep Problems...mentioning

confidence: 99%

Recent advances in understanding of sleep disorders and disturbances for dementia risk and prevention

Lam,

Kong,

Naismith

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

show abstract

Deregulation of Melatonin Receptors and Differential Modulation of After‐Hyperpolarization and Ih Currents Using Melatonin Treatment Due to Amyloid‐β‐Induced Neurotoxicity in the Hippocampus

Eslamizade,

Saffarzadeh,

Khatami

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Treatment with melatonin is routinely prescribed for its potent antioxidant and cognitive‐promoting effects, nevertheless, it has yet to find neuromodulatory effects in normal and disease conditions. Therefore, to investigate its neuromodulatory mechanisms, melatonin was systemically administered over 10 consecutive days to both intracortical normal saline‐ and amyloid‐β 1‐42 (Aβ) peptide‐injected rats. At the behavioral level, treatment with melatonin was associated with reduced efficacy in restoring Aβ‐induced deficit in passive‐avoidance memory. Whole‐cell patch‐clamp recordings from CA1 pyramidal neurons revealed that melatonin treatment reduced spontaneous and evoked intrinsic excitability in control rats while exerting a reduction of spontaneous, but not evoked activity, in the Aβ‐injected group. Interestingly, treatment with melatonin enhances after‐hyperpolarization in control, but not Aβ‐injected rats. In contrast, our voltage‐clamp study showed that Ih current is significantly enhanced by Aβ injection, and this effect is further strengthened by treatment with melatonin in Aβ‐injected rats. Finally, we discovered that the transcription of melatonin receptors 1 (MT1) and 2 (MT2) is significantly upregulated in the hippocampi of Aβ‐injected rats. Collectively, our study demonstrates that systemic treatment with melatonin has differential neuromodulation on CA1 neuronal excitability, at least in part, via differential effects on after‐hyperpolarization and Ih currents due to Aβ‐induced neurotoxicity.

show abstract

The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis

et al. 2023

View full text Add to dashboard Cite

EEG coherence and power spectra during REM sleep related to melatonin intake in mild-to-moderate Alzheimer’s disease: a pilot study

Cited by 5 publications

References 59 publications

Recent advances in understanding of sleep disorders and disturbances for dementia risk and prevention

Recent advances in understanding of sleep disorders and disturbances for dementia risk and prevention

Deregulation of Melatonin Receptors and Differential Modulation of After‐Hyperpolarization and Ih Currents Using Melatonin Treatment Due to Amyloid‐β‐Induced Neurotoxicity in the Hippocampus

The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis

Contact Info

Product

Resources

About